0.03 t 0.01 vs. intravenous: 3.1 ? 0.6 pg/kg; P < 0.001). The intravenous administration of ifetroban (10 pg/kg) caused a greater (P < 0.02) inhibition of pressor responses to U-46,619 (1 pg/kg) given intravenously (81 t 3%) compared with U-46,619 given intracerebroventricularly (40 2 13%). In conclusion, TxA2/PGH2 receptor mRNAis expressed in neurons, glial, and brain stem of normal rats. The central administration of a Tx&/PGH2 mimetic raises blood pressure by interaction with specific central and peripheral receptors.
This response is augmented in rats fed a high-salt compared with a low-salt diet.
angiotensin II-induced hypertension (12, 13, 33) , and 2-kidney, l-clip renovascular hypertension (2).
In previous studies, systemic infusion of the TxAz mimetic U-46,619 for 14 days into conscious rats led to progressive increases in blood pressure (BP) that were abolished by anesthesia or blockade of the sympathetic nervous system with phenoxybenzamine (27) . This suggests the involvement of the central and/or peripheral sympathetic nervous systems. The rise in BP was potentiated by feeding a high-salt diet. Recently, Kitanaka et al. (11) have reported the expression of mRNA for TxA2/PGH2 receptors in rat astrocyte cells. The metabolite of TxA,, TxBz, is released from the rat hypothalamus in vivo (24). There is a massive release of TxBz into the cerebral circulation of goats during hypotension (4). These results suggest that TxAg/PGH2 receptors can be expressed in the brain and might function in BP control. However, a previous physiological study involving central administration of a TxA,/ PGHz mimetic reported pressor responses in spontaneously hypertensive rats, but not in normotensive Wistar rats fed a normal salt intake (23). The present studies were designed to investigate whether mRNA for TxA,/ PGH2 receptors is expressed in rat neural and glial cells and brain and to reinvestigate the BP responses to central and peripheral administration of graded doses of U-46,619 in normotensive, conscious SpragueDawley rats. The responses to U-46,619 were contrasted in rats fed low and high salt intakes. Because a high salt intake was found to enhance the response to intracerebroventricular administration of U-46,619, this was the model used in subsequent protocols in this study.
METHODS thromboxane
A,; prostaglandin HZ; blood pressure; brain; hypertension; thromboxane receptor; U-46,619; ifetroban THROMBOXANE (TX) Az/prostaglandin (PG) Hz receptors can be activated by a number of agonists, including Tx&, prostaglandin endoperoxides (13), and U-46,619 (16). TxAZ/PGH2 receptors mediate many vascular and renal actions, including endothelium-dependent constrictor responses in hypertensive rats (22), renal (32) and systemic (7) vasoconstriction, enhanced reabsorption of chloride in the loop of Henle (31), and enhanced tubuloglomerular feedback responses in the kidney (28, 29, 31) . TxAZ/PGH2 receptor activation has been implicated in the development of hypertension in several animal models, including genetic hypertension (lS), Animal preparation.
Male Sprague-Dawley rats (280-350 g) were maintained on a rat chow with a low (0.03 g/l00 g) or high (2.4 g/l00 g) Na content (Teklad, Madison, WI) with tap water to drink. A high salt intake was used in all studies after series 1 because we found that it potentiated the rise in BP during prolonged infusion of U-46,619 (27) , potentiated the tubuloglomerular feedback responses to U-46,619 (30) , and potentiated the response to intracerebroventricular administration of U-46,619 (series 1). Rats were anesthetized with pentobarbital sodium (50 mg/kg ip; Abbott Labs, North Chicago, IL). With the use of a stereotaxic frame (David Kopf, Tujunga, CA), the skull was immobilized and drilled, and a 23-gauge stainless steel guide cannula was lowered 5 mm into the lateral cerebral ventricle, which was located 1.4 mm lateral and 0.9 mm posterior to the bregma. After insertion of two stainless steel anchoring screws, dental acrylic was applied to secure the guide cannula in the skull and sealed with a 30-gauge stainless steel obturator carefully placed in the lumen. Approximately 3 days after implanting the intra-
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BRAINTx&RECEPTORSANDBP cerebroventricular cannula, rats were anesthetized with pentobarbital sodium and a PE-10 catheter, connected to a PE-50 catheter, was placed in a femoral artery and a PE-50 catheter in a femoral vein. Catheters were threaded subcutaneously and exteriorized at the nape of the neck, where they were protected by a light, flexible metal spring secured to a plate that was sutured to the skin. Catheters were flushed and filled with a solution of 500 IU/ml of heparin and 1,000 IU/ml penicillin G in 0.154 M NaCl. After recovery from anesthesia, rats were placed in individual metabolism cages with free access to food and water. The metal spring attachment and cannula were connected to a swivel to permit freedom of movement. Catheters were flushed daily.
The rats were allowed 3 days to recover from surgery. Experiments were performed on rats in the conscious and unrestrained state. The arterial line was connected to a pressure transducer to record the mean arterial pressure (MAP) and heart rate (HR) on a computer monitoring system (MacLab 4E; AD I ns t ruments, Milford, MA). For intracerebroventricular injections, the obturator was removed and replaced with an injector inserted via the guide cannula and connected to a microsyringe via a PE-20 catheter. This whole system was filled with the test solution, and the desired volume (10 ~1) was injected when required. The position of the intracerebroventricular cannula was confirmed at the end of the experiments by injection of methylene blue and postmortem examination of the brain. Experimental protocok.
The aim of the first series was to compare the effects of salt intake on the dose-response relationships for U-46,619 administered intravenously or intracerebroventricularly.
Diets were identical except in salt content (Teklad, Madison, WI) . Groups of rats were accommodated to a low-salt (n = 6; Na content 0.03 g/100 g) or a high-salt (n = 6; Na content 2.4 g/100 g) diet for 6-8 days before testing. They were habituated to the metabolic cages for 3 days to become accustomed to the experimental environment. Their BP was recorded continuously for 30 min or until it became stable. Baseline measurements of MAP and HR were made over 30 min, and the data were meaned. Thereafter, rats were given graded doses of U-46,619 (0.1,0.3,1, and 3 pg/kg) or vehicle intracerebroventricularly or intravenously at intervals of 20 min, or longer if required for BP to return to baseline levels. Measurements of MAP and HR were made at 1,3,10, and 15 min after injections. The order of intravenous and intracerebroventricular injections was randomized. At least 24 h was allowed between intravenous or intracerebroventricular testing. The aim of the second series was to assess what fraction of U-46,619 given intracerebroventricularly gained access to the systemic circulation.
Rats were fed a high-salt diet and were given [3H]U-46,619
[2,250,000 disintegrations/min (dpm); New England Nuclear Products, Boston, MA] either intracerebroventricularly or intravenously. Blood was drawn before and at 1, 3, 10, and 15 min after injections.
Plasma (10 ~1) samples were counted in triplicate in a liquid scintillation counter.
The aim of the third series was to contrast the effects of a TxAz/PGHz receptor antagonist ifetroban (BMS-180,291) (16) on the central and peripheral responses to U-46,619 in rats fed a high-salt diet. A dose of 1 pg/kg of U-46,619 was chosen for central and peripheral injections because this was found to produce a reproducible pressor response of -20 mmHg. Ifetroban was given in graded doses of 0.001, 0.01, 0.1, 1, and 10 pg/kg or equivalent vehicle. BP was recorded 1 min after injections.
The Tx&/PGHz mimetic and antagonist were coadministered by the intracerebroventricular route, but for the intravenous route the antagonist was given 1 min before the agonist. The order of central and peripheral testing was randomized, and studies were undertaken on separate days. The aim of the fourth series was to assess the relative contributions of central and peripheral Tx&/PGH2 receptors to the rises in BP produced by intracerebroventricular or intravenous injections of U-46,619 (1 pg/kg). First, the vehicle or ifetroban (10 pg/kg) was administered intravenously, and 1 min later U-46,619 was administered intravenously or intracerebroventricularly.
Second, the vehicle or ifetroban (0.1 pg/kg) was administered intracerebroventricularly, and 1 min later U-46,619 was administered intravenously or intracerebroventricularly.
The changes in MAP were recorded 1 min after administration of vehicle or U-46,619. All four studies were conducted on separate days.
The aim of the fifth series was to determine whether mRNA for TxA#GH2 receptors was expressed in rat brain and glomeruli and in rat neural or glial cells in culture. The kidney and brain of male Sprague-Dawley rats fed a normal salt intake were harvested. The cerebellum and cortex of the brain were excised, and total RNA was extracted from the remaining brain tissue using RNA ATAT-(Tel-test B, Friendswood, TX). The astroglial cells and neuronal cells were harvested from brains of Wistar rats fed a normal salt intake and were kindly provided by Dr. M. Raizada (University of Florida, Gainesville, FL). These rats were fed a chow with a sodium content of 0.3 g/l00 g throughout.
Hypothalamus-brain stem areas of l-day-old rat brains were dissected, and brain cells were dissociated by trypsin. The hypothalamic block contained the paraventricular nucleus and the supraoptic, inferior, lateral, posterior, dorsal, medial, and ventralmedial nuclei. The brain stem block contained medulla oblongata and pons. Dissociated brain cells were plated onto poly-L-lysine-precoated tissue cultured dishes (18 X lo6 cells per loo-ml diameter dishes) in a Dulbecco's modified Eagle's medium containing 10% plasma-derived horse serum. Neuronal cultures were established as described previously (26). Cultures were allowed to grow for lo-15 days before their use in the experiments. Astroglial cultures were prepared from the same hypothalamic-brain stem areas of l-day-old rats, as described previously (26). Trypsin-dissociated brain cells suspended in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum were plated in loo-ml culture dishes (18 X lo6 cells per dish). Cells were grown for 6 days at 37°C in 5% COZ-95% air. They were dissociated from dishes by trypsin and replated in loo-ml culture dishes (1 X lo6 cells per dish). They were allowed to grow for lo-15 days before being used in the experiment. The procedure for microdissection of glomeruli was conducted as previously reported (17). The mRNA from the glomeruli, brain stem, and astroglial and neuronal cells was reverse transcribed (RT) with oligo(dT)16 as primer and MuLv reverse transcriptase using an RNA polymerase chain reaction (PCR) kit (Perkin Elmer, Branchburg, NJ). The primers used for PCR for the TxA2/ PGHz receptor gene product were selected from the published cDNA sequence of the rat TxA#GHz receptor (1). Data were assessed by analysis of variance (ANOVA) with repeated measures. Where appropriate3 Dunnett's tests were applied to detect post hoc differences between groups. Data are shown as means t SE values, and statistical significance was taken at P < 0.05.
RESULTS
The MAP of rats receiving the high-salt diet did not differ between series and averaged 109 t 9 mmHg. This value is not significantly different from the average MAP of rats receiving the low-salt diet of 115 ? 3 mmHg. Administration of vehicle by the intravenous or intracerebroventricular route did not change MAP consistently (intravenous: + 1.2 t 1.3; intracerebroventricular: +1.2 t_ 0.8 mmHg). Series 1. This series contrasted the effects of salt intake on the responses to U-46,619. Administration of U-46,619 by intravenous (Fig. 1A) or intracerebroventricular (Fig. 1B) injection produced graded, dosedependent rises in MAP 1 min after administration, accompanied by reductions in HR ranging from 10 beats/min (bpm) at the lowest dose to 50 bpm at the highest dose (data not shown). Changes in HR were similar after intravenous or intracerebroventricular administration. As shown in Fig. lA , the pressor responses to intravenous U-46,619 were similar in lowand high-salt rats. In contrast, as shown in Fig. lB , the early and later rises in MAP after intracerebroventricular U-46,619 were significantly greater in high-salt rats.
Series 2. This series contrasted the responses to intravenous and intracerebroventricular administration of U-46,619 to high-salt rats. The early pressor responses 1 min after intracerebroventricular administration of higher doses of U-46,619 were greater than to intravenous administration, and this difference was significant at the highest dose level tested (Fig. 2) . The time course of the pressor responses were different (Fig.  3) . Whereas the MAP returned to a value close to baseline by 15 min after intravenous injection, it remained more elevated at 10 and 15 min after intracerebroventricular injection. At 15 min, the increases in MAP above baseline after intracerebroventricular injec- n = 6) or a low-salt (0; n = 6) diet for 6-8 days before testing. Comparing low-salt and high-salt data: *P < 0.05; **P < 0.01.
tion of U-46,619 at doses of 0.3 mg/kg and above were significantly higher than after intravenous injections. Series 3. The aim of this series was to evaluate the rate at which centrally administered [3H]U-46,619 gained access to the peripheral circulation. The plasma 3H radioactivity after injections of 2,251,OOO dpm of E3H]U-46,619 (equivalent to 0.1 rig/kg) given intravenously or centrally is shown in Fig. 4 . Within 1 min of central injection, radioactivity was detected in the plasma at a level equivalent to -20% of that after a comparable intravenous injection. Thereafter, the plasma radioactivity levels after intracerebroventricular injection remained 20-40% of that after intravenous injection. ventricularly (ifetroban 0.1 pg/kg: MAP change + 1.3 2 2.0 mmHg). It is apparent -that ifetroban -produced >90% blockade of the pressor responses to intravenous or intracerebroventricular U-461619. However, there was a marked difference in the sensitivity of the blocking response. Calculation of the mean dose required to provide 50% blockade (I(&) showed that ifetroban was much more sensitive after intracerebroventricular administration (P < 0.001) in blocking the pressor response (KS0 36 t 17 rig/kg) than after intravenous administration (ICsO 3,100 t 609 rig/kg).
Series 5. As in series 2, the intravenous injection of ifet )roban (10 pg/kg), produced a substantial blockade of the pressor response to intravenous injection of U-46,619 (1 pgkg; Fig. 6A ). The intravenous administration of ifetroban in the same dose blocked only about one-half of the pressor response to intracerebroventricular administration of U-46,619 (1 pg/kg). Thus about one-half of the pressor response to U-46,619 given centrally is unresponsive to blockade by ifetroban given peripherally and therefore is presumably mediated by receptors in the brain. The intracerebroventricular injection of ifetroban (0.1 pglkg) produced a substantial blockade of the pressor response to intracerebroventricular U-46,619 (1 pg/kg; Fig. 6B ). The intracerebroventricular administration of ifetroban in the same dose blocked only about one-half of the response to intravenous administration of U-46,619 (1 pg/kg). Therefore, about one-half of the pressor response to U-46,619 given intravenously 1s unresponsive to ifetroban given centrally and, therefore, is presumably mediated by receptors outside the brain.
Series 6. Figure 7 shows PCR products from mRNA extracted from the brain stem of adult Sprague-Dawley rats fed a normal salt intake. All studies were amplified for 40 cycles. A strong band is apparent in the presence (+), but not in the absence (-), of reverse transcription.
The RT product from rat brain stem was eluted and purified. Its sequence had 100% concordance with the published sequence from rat kidney (1).
As shown in Fig. 8 , the PCR products from mRNA extracted from kidney glomeruli of Sprague-Dawley rats fed a normal salt diet and from astroglial and neuronal cells in culture from the brains of Wistar rats fed a normal salt diet yielded strong bands in the presence, but not in the absence, of reverse transcription. The bands corresponded in size to the cDNAprobe for rat TxAJPGH2 receptor. The control lane shows the absence of RT products from the buffer used. All studies were amplified for 40 cycles.
DISCUSSION
The results of the present study provide the first evidence for a central pressor pathway mediated by TxA2/PGH2 receptors expressed in the brain of normotensive rats. Siren et al. (23) had reported that intracerebroventricular injection of U-46,619 induced a doserelated increase in MAP in spontaneously hypertensive rats but did not alter the BP of normotensive rats. They studied doses of U-46,619 equivalent to those in the present study where we found the threshold intracerebroventricular dose for U-46,619 to be -0.1 pg/kg. The reason for the differences in response to intracerebroventricular U-46,619 between these studies is not clear but may relate to the rat strain. Siren et al. (23) studied Wistar rats, whereas the present study used SpragueDawley rats. It cannot be ascribed to the high salt intake used in the present protocols because we found that there were strong pressor responses to intracerebroventricular administration of U-46,619 in SpragueDawley rats given either a high-or a low-salt diet. However, the pressor responses of rats fed a high-salt diet, compared with a low-salt diet, were enhanced for intracerebroventricular but not for intravenous administration of U-46,619. This suggests that a high salt intake may potentiate brain TxA2/PGH2 receptor expression or responsiveness. We had found previously that prolonged peripheral administration of U-46,619 increased the systolic BP to a greater extent in rats fed a high-salt than a normal or low-salt diet (27). However, this effect of salt intake was seen only after 8-12 days of administration of U-46,619 and is consistent with the present finding that the early response to peripheral administration of U-46,619 is not enhanced by a high salt intake.
An analysis of the central cardiovascular effects of U-46,619 is complicated by the extreme lipid solubility of the compound (olive oil:water partition coefficient 66:34) (31) and the sensitivity of the peripheral circulation to it (threshold dose for pressor response +O-l" M/kg). As a consequence, centrally administered U-46,619 gains rapid access to the peripheral circulation and could raise BP by peripheral actions. Indeed, examination of the dose-response relationships for centrally and peripherally administered drug assessed 1 min after administration to high-salt rats showed a similar sensitivity but an increased responsiveness to intracerebroventricular administration at the highest Comparing intravenous and intracerebroventricular data: *P < 0.05; **P < 0.01; ***p < 0.005. doses (Fig. 2) . However, the time course of the pressor responses differed. After intravenous administration, the MAP returned to values very close to baseline within 15 min, whereas after intracerebroventricular administration the pressor responses were more sustained (Fig. 3) .
Further studies were undertaken to assess the contribution of peripheral actions of U-46,619 to the pressor response after central injection. Radiolabeled U-46,619 appeared in the peripheral circulation within 1 min after central injection in a concentration that was 20% of that after equivalent intravenous injections. Thus centrally injected U-46,619 rapidly leaves the brain and enters the peripheral circulation where it interacts with peripheral receptors to raise the BP. The MAP was increased similarly by low doses of intracerebroventricularly or intravenously administered U-46,619 1 min after injection, despite the plasma 3H concentration after intracerebroventricular administration being only 20% that after intravenous injection. This suggests that much of the earlv pressor response to intracerebro- (1 pg/kg) by ifetroban after both drugs were given intravenously (0; n = 7) or intracerebroventricularly (0; IZ = 7) to rats fed a high-salt diet. Comparing intravenous and intracerebroventricular data: +P < 0.05; + + P < 0.01; + + + P < 0.001.
A -20 ventricular administration originated from actions of U-46,619 within the brain. Moreover, at 15 min, the plasma concentration of 3H after intracerebroventricular injection was ~40% of that after intravenous injection, yet the MAP was clearly higher. Thus, at this time, most of the pressor response was centrally mediated. The relative importance of central and peripheral TxAJPGH2 receptors in the response to centrally administered U-46,619 was examined further by comparing the efficacy of intravenous ifetroban in blocking the pressor responses to intracerebroventricular and intravenous administration of U-46,619 to high-salt rats. Intravenous ifetroban, in a dose that blocked almost all of the pressor response to intravenous U-46,619, blocked less than one-half of the response to intracerebroventricular U-46,619. Likewise, centrally administered ifetroban was more effective in blocking the pressor response to intracerebroventricular than to intravenous U-46,619. Taken together, these observations suggest that the pressor responses after central or peripheral administration of U-46,619 are due to combined actions of the drug in the brain and the peripheral circulation. At least one-half of the pressor responses to intracerebroventricular U-46,619 are due to actions in the brain, and at least one-half of the pressor responses to intravenous U-46,619 are due to actions in the peripheral circulation.
Further evidence for central actions of U-46,619 came from studies that contrasted the blockade by ifetroban of the responses to U-46,619 when both agents were administered centrally or peripherally. Coadministration of ifetroban blocked >90% of the pressor responses to intravenously or intracerebroventricularly administered U-46,619. These results confirm that the cardiovascular responses to U-46,619 are receptor mediated (6, 7, 32 have shown TxAZ receptors linked to activation of phospholipase C in human (15) and rabbit (14) astrocytes. The present studies demonstrate that brain neurons are also potential sites of action of TxAz or other endogenous ligands for this receptor.
In conclusion, mRNA for TxAJPGHs receptors is expressed in the brain stem and in neuronal and astroglial cells of normal rats. Studies with a specific TxA2/PGH2 receptor agonist demonstrate that activation of these receptors within the brain can raise BP and that salt loading enhances this response.
Perspectives
The mechanism of the central pressor response to U-46,619 remains to be explored. In previous studies, we found that prolonged subcutaneous infusions of U-46,619 via an osmotic minipump raised the systolic BP progressively. This hypertensive response depended on an intact sympathetic nervous system because it was abolished by a-adrenergic blockade with phenoxybenzamine (27) 
